482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rezatapopt Prostate Cancer	PMV Pharmaceuticals, Inc	P1/2	CC (40)
Rifaximin Prostate Cancer	Mansoura University	P1/2	CC (40)
SL-28 Prostate Cancer	Second Life Therapeutics	P1/2	CC (40)
Solnerstotug Prostate Cancer	Sensei Biotherapeutics, Inc.	P1/2	CC (40)
st101 Prostate Cancer	Sapience Therapeutics	P1/2	CC (40)
SX682 Prostate Cancer	National Cancer Institute (NCI)	P1/2	CC (40)
Tazemetostat Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CC (40)
tb511 Prostate Cancer	Twinpig Biolab, Inc.	P1/2	CC (40)
T-Cell Receptor-Engineered T-Cells Prostate Cancer	Fred Hutchinson Cancer Center	P1	CC (40)
T-Dxd Prostate Cancer	AstraZeneca	P1/2	CC (40)
Tipiracil Prostate Cancer	Parabilis Medicines, Inc.	P1/2	CC (40)
tng348 Prostate Cancer	Tango Therapeutics, Inc.	P1/2	CC (40)
Trifluridine Prostate Cancer	Parabilis Medicines, Inc.	P1/2	CC (40)
Verteporfin Prostate Cancer	SpectraCure AB	P1/2	CC (40)
Vio-01 Prostate Cancer	Valerio Therapeutics	P1/2	CC (40)
xnw5004 Prostate Cancer	Evopoint Biosciences Inc.	P1/2	CC (40)
68Ga-AAZTA-093 Prostate Cancer	First Affiliated Hospital of Fujian Medical University	Early P1	C (39)
[68ga]ga-oncoacp3 Prostate Cancer	Philogen S.p.A.	P1	C (39)
68ga-labeled ny108 Prostate Cancer	Affiliated Hospital of Jiangnan University	Early P1	C (39)
[99mTc]Tc-BQ0413 Prostate Cancer	Tomsk National Research Medical Center of the Russian Academy of Sciences	P1	C (39)
Agn-Cogni.Q Prostate Cancer	Milton S. Hershey Medical Center	P1	C (39)
Gedatolisib Prostate Cancer	Celcuity Inc	P1/2	C (39)
IBI311 Prostate Cancer	Shanghai Changzheng Hospital	Early P1	C (39)
Rifaldazine Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1	C (39)
Sol-804-F Prostate Cancer	Bukwang Pharmaceutical	P1	C (39)
Pacritinib Prostate Cancer	Medical College of Wisconsin	P2	C (38)
Vudalimab Prostate Cancer	Emory University	P1	C (37)
[177Lu]Lu-A9-0631 Prostate Cancer	Alpha-9 Oncology USA Inc.	P1	C (36)
[225Ac]Ac-A9-0642 Prostate Cancer	Alpha-9 Oncology USA Inc.	P1	C (36)
[225Ac]Ac-AKY-2519 Prostate Cancer	Aktis Oncology, Inc.	P1	C (36)
225ac-psma-r2 Prostate Cancer	Novartis Pharmaceuticals	P1	C (36)
[64Cu]Cu-AKY-2519 Prostate Cancer	Aktis Oncology, Inc.	P1	C (36)
68ga-nta-476 Prostate Cancer	Melbourne Theranostic Innovation Centre	Early P1	C (36)
89zr-dfo-psmai-peg-cy5.5-c' dots Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1	C (36)
[Ac-225]-Psma-62 Prostate Cancer	Eli Lilly and Company	P1	C (36)
Actinium (225Ac) Psma-617 Prostate Cancer	Thomas Hope	P1	C (36)
agx101 Prostate Cancer	Angiex, Inc.	P1	C (36)
Amg 509 Prostate Cancer	Amgen	P1	C (36)
Balstilimab Prostate Cancer	Agenus Inc.	P1	C (36)
bg-68501 Prostate Cancer	BeiGene	P1	C (36)
Bgb-43395 Prostate Cancer	BeiGene	P1	C (36)
Blood, Whole Prostate Cancer	Mayo Clinic	P1	C (36)
Botensilimab Prostate Cancer	Agenus Inc.	P1	C (36)
Bp-C2 Prostate Cancer	Meddoc	P1	C (36)
Bpx-601 Prostate Cancer	Regeneron Pharmaceuticals	P1	C (36)
Brodalumab Prostate Cancer	Brian Henick, MD	P1	C (36)
Cart-Psma Cells Prostate Cancer	Nova Therapeutics LLC	P1	C (36)
Cart-Psma-Tgfβrdn Cells Prostate Cancer	University of Pennsylvania	P1	C (36)
Clsp-1025 Prostate Cancer	Clasp Therapeutics, Inc.	P1	C (36)
Dat-2645 Prostate Cancer	Danatlas Pharmaceuticals Co., Ltd	P1	C (36)

Showing 351 to 400 of 482 assets

PreviousPage 8 of 10Next